Business Context and Reporting Period
This Form 8-K was filed by Syndax Pharmaceuticals, Inc. on July 4, 2019. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of an executive officer to the Board.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and board composition.
Material Changes
- Board Expansion: The Board of Directors increased its size to eight members.
- Director Election: Michael A. Metzger, President and Chief Operating Officer, was elected to the Board as a Class I member effective immediately.
- Compensation Adjustment: Mr. Metzger's annual base salary was increased to $560,000.
- Equity Grant: Mr. Metzger was granted a stock option to purchase 200,000 shares of common stock at an exercise price of $9.15 per share.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The stock option granted to Mr. Metzger is subject to vesting in equal monthly amounts over a four-year period, contingent upon his continued service.
Investor Verification Checklist
- Verify the total number of shares outstanding to assess the dilution impact of the 200,000 share option grant.
- Review the definitive proxy statement for details on Mr. Metzger's existing compensation, termination, and change-in-control arrangements.
- Confirm the current market price of Syndax Pharmaceuticals common stock relative to the $9.15 exercise price of the new option.